Vis børsmeldingen
over the world.
Data from two Hexvix studies were presented at the congress:
Antitumor effect and induced systemic immune effects of HAL and blue light in an
orthotopic model of rat bladder cancer, presented by Kari Myren, MD, Head of
Global Medical Affairs and Clinical Development, Photocure, Oslo, Norway. These
are the first published data from a pre-clinical study investigating potential
treatment effects of Blue Light Cystoscopy (BLCT) with Hexvix. The results of
the study indicate for the first time that a treatment effect could be related
to immunogenic cell death responses and anti-tumor immune cell activation.
Here is a link to the abstract: https://bit.ly/2kKnE7Y
The second abstract was based on results from the Nordic registry study with
Hexvix and flexible cystoscopes in the office setting: Malignant urinary
cytology of unknown origin - blue light flexible cystoscopy with
Hexaminolevulinate (HAL) at the outpatient clinic may be a valuable diagnostic
and therapeutic tool, presented by Marie Andersson, Department of Urology,
Helsingborg hospital, Sweden.
The author concluded that flexible BLC with flexible cystoscopes in the
outpatient clinic may in a simple way solve many unclear cases with malign or
suspicious urinary cytology. The procedure is well tolerated and generally
preferred by patients over a procedure in the operating room under general
anesthesia.
Here is a link to the abstract: https://bit.ly/2kzsRQf
“It is encouraging to see new data on Hexvix being presented at an international
bladder cancer expert congress, clearly showing the immense potential Hexvix
has. The flex study demonstrating how using Hexvix in the outpatient
clinic/office can solve challenging cases for the benefit of patients and
providers, and the first pre-clinical data indicating that Blue Light cystoscopy
with Hexvix might have a treatment effect. These early data are very exciting,
and we look forward to exploring this further”, says Dan Schneider, President
and CEO of Photocure.
About Bladder Cancer
Bladder cancer ranks as the ninth most common cancer worldwide with 430 000 new
cases and more than 165 000 deaths annually. Approx. 75% of all bladder cancer
cases occur in men[1]. It has a high recurrence rate with an average of 61% in
year one and 78% over five years[2]. Bladder cancer has the highest lifetime
treatment costs per patient of all cancers[3].
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3 and T4, are more likely to spread and are harder to treat[4].
About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.
Cysview[®] is the tradename in the US and Canada, Hexvix[®] is the tradename in
all other markets. Photocure is commercializing Cysview[®] / Hexvix[®] directly
in the US and the Nordic region and has strategic partnerships for the
commercialization of Hexvix[® ]/ Cysview[®] in Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our
commercial partners.
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.
References
- Globocan. Incidence/mortality by population. Available
at: http://globocan.iarc.fr/Default.aspx
- Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.
EAU Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol.
2016 Guidelines Edition:1-40.
- Sievert KD et al. World J Urol 2009;27:295-300
- Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html
For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com
Kilde
